Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
Cell & Gene Therapy Webinars
Whole Genome Single-Cell Measurement of Structural Variation
Thursday 02 September 2021 | 16:00 BST (UTC+1)
Directional Genomic Hybridization (dGH) is a single-cell, analytical platform used by researchers and drug developers to help bolster the safety profiles of their therapeutic candidates. This presentation will focus on the latest iteration of this technology, dGH SCREEN. SCREEN can be used to track structural rearrangements throughout the genome that are difficult or impossible to track with sequencing, with an order of magnitude improvement in resolution over G-Banding.
- dGH SCREEN is a new cytogenetic analytical technique with an order of magnitude improvement in resolution over G-Banding.
- dGH SCREEN has already found previously unknown rearrangements in the most sequenced genome on earth.
- dGH SCREEN can be used to monitor effects of cellular engineering processes on genomic stability.
ERIN CROSS, Associate Director of Whole Genome R&D at KromaTiD
Erin Cross is the lead development scientist for whole genome research at KromaTiD. As one of its first employees, she has pioneered KromaTiD’s flagship technology, directional Genomic Hybridizaiton, for the use of unbiased, single-cell assessments of genomic structural rearrangements. With over ten years of experience in molecular biology, virology, and genetics, she has helped lead KromaTiD to the forefront of cytogenetic and cellular engineering research.
CHRIS TOMPKINS, Chief Technology Officer at KromaTiD
With over 25 years of experience developing and launching biotechnology, diagnostic and pharmaceutical products, Dr. Tompkins serves as KromaTiD’s Chief Technology Officer where he leads the teams launching KromaTiD’s genomic structural products and services for Gene Editing and Gene Therapy. Prior to KromaTiD, Dr. Tompkins led development teams at Roche, Degussa, NexStar and Proligo responsible for launching two marketed pharmaceutical products, siRNA production, large scale oligonucleotide production and numerous diagnostic and biotechnology products.
Streamlining Process Monitoring in Cell Culture Analysis and Spectrometry
Tuesday 21 September 2021 | 16:00 BST (UTC+1)
- Femi Egbebi, PhD; Senior Global Product Manager; Thermo Fisher Scientific
- Daniel Merriman; Strategic Marketing Manager; Thermo Fisher Scientific
- Krzysztof Inglot, PhD; Technical Sales Specialist; Thermo Fisher Scientific
- BEA process monitoring capabilities
- Mass Spectrometry
- Prima PRO
FEMI EGBEBI, PhD; Senior Global Product Manager at Thermo Fisher
Femi Egbebi is the Senior Global Product Manager for Media Development Services / Omics capabilities at Bioproduction Group of Thermo Fisher Scientific. He has an MBA from Carnegie Mellon University and a PhD in Chemical Engineering from the Louisiana State University. Prior to joining Thermo Fisher in 2018, he held various technical research roles at major engineering firms.
DANIEL MERRIMAN, Strategic Marketing Manager at Thermo Fisher
Daniel Merriman joined VG Instruments, now Thermo Fisher Scientific in 1988. Currently a strategic marketing manager, he has held many roles associated with online process analytics and particularly mass spectrometry. During his career he has worked extensively to advance the use of online mass spectrometry as a Process Analytical Technology (PAT) in the biotechnology sector, working with industry and academia to develop applications for monitoring fermentation and cell culture processes. Daniel has recently co-authored papers with University College London and the National Institute for Bioprocess Research & Training (NIBRT) about mammalian cell culture monitoring by online mass spectrometry.
KRZYSZTOF INGLOT, PhD; Technical Sales Specialist at Thermo Fisher
Krzysztof Inglot joined Thermo Fisher Scientific in 2017, with more than fifteen years’ experience working in the bioprocess sphere. In his current role as Technical Sales Specialist, he primarily supports single-use technologies, specializing in hardware configuration and our TruBio software. Along with his team, his experience allows Thermo Fisher to integrate different equipment and sensors from upstream and downstream areas. He has a PhD in Engineering from the Poznan University of Technology.
TESSA Technology: A Plasmid-Free, Scalable System to
Transform AAV Manufacture
Wednesday 13 October 2021 | 16:00 BST (UTC+1)
Ryan Cawood, Chief Scientific Officer, OXGENE/WuXi ATU